◉ Colloquy — research, out loud
Frontiers in Pharmacology · 2026 · doi:10.3389/fphar.2026.1893236
Introduction Morphine tolerance limits its long-term clinical utility, and neuroinflammation is a key underlying mechanism. This study investigated whether zonisamide, an antiepileptic drug with anti-inflammatory properties, attenuates morphine-induced morphine tolerance. Methods In vitro, BV-2 microglial cells were treated (200 μM) or without zonisamide (10 μM). Quantitative real-time PCR, enzyme-linked immunosorbent assay (ELISA), Western blot analysis used to assess inflammatory mediators signaling pathways. vivo, male C57BL/6 mice received repeated injections mg/kg, s.c., twice daily) for 9 days induce tolerance, (30 i.p.). Behavioral tests (hot plate tail flick) performed evaluate analgesic Immunofluorescence was activation (Iba1), analyses conducted TLR4 expression, p38 phosphorylation, pro-inflammatory cytokine protein levels. Pharmacological inhibition of TAK-242 verify the involvement signaling. Results suppressed upregulation interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, Toll-like receptor 4 (TLR4) mRNA, reduced secretion IL-1β, TNF-α at level, inhibited mitogen-activated kinase (MAPK) phosphorylation. did not affect acute analgesia but significantly attenuated development chronic Spinal cord revealed that (IL-1β, TNF-α) produced behavioral effect similar combined treatment provide additional benefit, suggesting overlapping effects. Discussion These findings indicate in association spinal TLR4/p38 MAPK neuroinflammation. provides mechanistic rationale repurposing as adjunct therapy improve pain management mitigate opioid-related adverse
Researcher A When you take morphine for pain day after day, your body stops listening. It's called tolerance, and it forces patients to keep raising the dose—which means more side effects, more addiction risk, and eventually, the drug just stops working. Today we're looking at a study that found an old epilepsy drug called zonisamide might be able to slow that tolerance down, without dulling morphine's immediate pain relief.
Researcher B That's a big claim. So zonisamide just... stops tolerance? What's the catch?
Researcher A The catch is it's preclinical—mice and cell cultures so far. No human trials yet. But the mechanism they found is pretty specific, and it points to something real happening in the spinal cord.
Researcher B Why is morphine tolerance such a problem that we need a whole new drug to fix it?
Researcher A Because it's a clinical dead end. In one prospective cohort of 517 chronic pain patients on stable opioid therapy, 19.5 percent had to escalate their dose—but escalation didn't actually improve their pain outcomes. So you're just adding risk without benefit.
Researcher B And we know why that happens?
Researcher A Yes—neuroinflammation. When morphine sits in the spinal cord, it activates immune cells called microglia. Those cells release inflammatory molecules: interleukin-1 beta, interleukin-6, tumor necrosis factor alpha. That inflammatory cascade is what actually drives tolerance. The morphine receptor itself isn't the problem; it's the immune response to morphine.
Researcher B So if you suppress that inflammation without blocking the opioid receptor, you could theoretically keep morphine working longer?
Researcher A Exactly. And zonisamide is already approved, already safe, already used in epilepsy. So if it works, you could repurpose it tomorrow.
Researcher B Walk me through the experiment.
Researcher A Two parts. First, in vitro: they took BV-2 microglial cells—that's a standard mouse microglial cell line—and treated them with morphine at 200 micromolar, with or without zonisamide at 10 micromolar, for 12 hours. They measured inflammatory markers using real-time PCR, ELISA, and Western blotting.
Researcher B Those are standard molecular biology techniques. What did they find?
Researcher A Morphine alone cranked up the messenger RNA for all three major inflammatory cytokines. Zonisamide suppressed that upregulation at the mRNA level and also reduced the actual protein secreted into the culture medium. Same story for TLR4—that's Toll-like receptor 4, the pattern recognition receptor that morphine hijacks to trigger inflammation.
Researcher B And in vivo?
Researcher A Male C57BL/6 mice—that's the standard inbred strain. They got morphine at 10 milligrams per kilogram, injected under the skin, twice a day for nine consecutive days. Half got zonisamide at 30 milligrams per kilogram injected intraperitoneally. They measured pain sensitivity using two behavioral tests: the hot-plate test—how long before the mouse jumps off a 55-degree surface—and the tail-flick test, where they measure how fast the mouse pulls its tail out of 52-degree water.
Researcher B And they measured this over the nine days to watch tolerance develop?
Researcher A Yes, on days 1, 3, 5, 7, and 9. They also did a separate acute experiment to make sure zonisamide didn't interfere with the immediate pain relief—they gave a single morphine dose with or without zonisamide and measured responses every 30 minutes for three hours. Then they killed the mice, pulled out the spinal cord dorsal horn, and measured microglial activation, TLR4 expression, p38 phosphorylation, and cytokine protein levels.
Researcher B What did they NOT do?
Researcher A They only tested one dose of zonisamide. Only male mice—no females. They used a cell line, not primary microglia. And they didn't do formal locomotor or motor-coordination tests, though they say they saw no overt sedation or impairment. They also didn't use genetic knockout mice to definitively prove TLR4 is necessary; they used a pharmacological inhibitor instead.
Researcher B Give me the numbers.
Researcher A In the cell culture: morphine upregulated IL-1 beta mRNA about 320-fold over control. Zonisamide co-treatment suppressed that dramatically—the statistical test was F of 3,8 equals 320.9, P equals 1.13 times 10 to the negative 8. Same for IL-6 and TNF-alpha. At the protein level, measured by ELISA, zonisamide reduced secreted IL-1 beta, IL-6, and TNF-alpha. For p38 phosphorylation—the key signaling step—zonisamide blocked that too.
Researcher B Those are big effect sizes.
Researcher A They are. Now in vivo: in the morphine-only group, the antinociceptive effect—the pain relief—declined progressively over nine days in both tests. That's tolerance. In the morphine-plus-zonisamide group, that decline was significantly attenuated. The area under the curve—which integrates pain sensitivity over the whole nine days—was substantially higher in the zonisamide group.
Researcher B But did zonisamide hurt the acute effect?
Researcher A No. When they gave a single morphine dose, there was no significant difference between morphine alone and morphine plus zonisamide at any time point over 180 minutes. The peak pain relief was identical. That's the key finding: zonisamide preserves acute analgesia but prevents chronic tolerance.
Researcher B What about the spinal cord?
Researcher A Morphine increased Iba1 protein—that's the microglial activation marker—in the dorsal horn. Zonisamide suppressed that. Same for TLR4 mRNA expression and phosphorylated p38. Pro-inflammatory cytokines IL-1 beta and TNF-alpha were elevated by morphine; zonisamide reduced those too. Immunofluorescence imaging confirmed the Iba1 suppression visually.
Researcher B Did they prove TLR4 is the mechanism?
Researcher A Partially. They used TAK-242, a TLR4 inhibitor, at 3 milligrams per kilogram. TAK-242 alone produced a protective effect similar to zonisamide. But when they combined them, there was no additional benefit—no synergy. That suggests they're hitting the same pathway. However, they note that this doesn't prove TLR4 is absolutely necessary; it just shows it's involved.
Researcher B What are the limitations?
Researcher A The authors themselves flag several. First, the in vitro work is in BV-2 cells, which is a cell line. Primary mouse microglia might behave differently. Second, only one dose of zonisamide was tested—no dose-response curve. Third, only males. Fourth, no formal motor or cognitive testing, though they didn't see overt problems.
Researcher B What else?
Researcher A They focused on TLR4 and p38 MAPK, but zonisamide might also modulate other pathways—NF-kappa-B, the NLRP3 inflammasome. They don't have cell-type-specific evidence that TLR4 and p38 are activated specifically in microglia, not astrocytes or other cells. They mention preliminary GFAP staining—that's astrocytes—suggesting zonisamide might affect those too, but they didn't pursue it.
Researcher B So the mechanism might be more complex than they're saying?
Researcher A Possibly. Worth noting beyond their list: this is a nine-day study in mice. Real chronic opioid use in humans is months or years. We don't know if the effect persists, if tolerance to zonisamide itself develops, or if there are long-term cognitive or dependence effects. And the TAK-242 experiment, while suggestive, doesn't prove causation—TLR4-knockout mice would be stronger evidence.
Researcher B Any safety concerns with zonisamide itself?
Researcher A They cite a pilot clinical study showing it's safe and tolerable in diabetic neuropathy patients. It's already approved for seizures. But combining it with morphine long-term—that hasn't been tested in humans yet.
Researcher A Three audiences. First: pain clinicians and anesthesiologists. If this holds up in human trials, it could extend the utility of morphine without escalating dose. That's a direct clinical win.
Researcher B Second?
Researcher A Neuroscientists studying neuroinflammation and opioid mechanisms. This paper strengthens the case that TLR4 and microglial activation are not just correlates of tolerance but causal drivers. And it shows that an existing, approved drug can target that pathway.
Researcher B And third?
Researcher A Drug-repurposing researchers. Zonisamide already has a safety database, already has regulatory approval. If the preclinical evidence holds, you could move to a Phase 2 trial relatively quickly without the full development cost of a new molecule.
Researcher B So it's not just about pain management—it's about the economics of drug development.
Researcher A Exactly.
Researcher A The full citation: Gei, L-B, Liu, Y-H, Guo, H, Zhao, X, Li, L-L, Zhang, R, Cheng, H-X, Feng, J-J, Zeng, W-A, Yan, Y, E, R-Q, and Chen, D-T. 2026. Zonisamide attenuates morphine tolerance in association with reduced spinal TLR4 slash p38 MAPK signaling. Frontiers in Pharmacology, volume 17, article 1893236. The D O I is 10 point 3389 slash fphar point 2026 point 1893236.
Researcher B And if someone wants to dig deeper?
Researcher A The thread is open on Colloquy.